184 related articles for article (PubMed ID: 17596116)
21. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
[TBL] [Abstract][Full Text] [Related]
22. A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin.
Moon A; Smith T
Clin Ther; 2002 Apr; 24(4):653-61. PubMed ID: 12017409
[TBL] [Abstract][Full Text] [Related]
23. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Holme I; Szarek M; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Pedersen TR;
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):315-20. PubMed ID: 19322096
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers.
Mendoza L; Hajdúch M; Plausinaitis R; Platílová V; Emritte N; Svoboda M
Pharmazie; 2006 Sep; 61(9):805-6. PubMed ID: 17020163
[TBL] [Abstract][Full Text] [Related]
26. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
28. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Gerber JG; Rosenkranz SL; Fichtenbaum CJ; Vega JM; Yang A; Alston BL; Brobst SW; Segal Y; Aberg JA;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):307-12. PubMed ID: 15980690
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Birnbaum Y; Lin Y; Ye Y; Merla R; Perez-Polo JR; Uretsky BF
J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):72-9. PubMed ID: 18287593
[TBL] [Abstract][Full Text] [Related]
30. Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population.
Song JC; Wang CC; Huang YC; Sanchez J; Nguyen T; Khan S; Kim MK; Li P
Am J Health Syst Pharm; 2007 Apr; 64(7):767-72. PubMed ID: 17384364
[TBL] [Abstract][Full Text] [Related]
31. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
[TBL] [Abstract][Full Text] [Related]
32. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
33. Ask the doctor. After a heart attack six years ago, I went on Lipitor (atorvastatin) because my doctor said it was proven to reduce the risk of a second heart attack in high-risk people like me. Three years ago, I switched to a generic (simvastatin) to save money. Now that Lipitor is going generic, should I switch back? And can I be assured that the generic version will be as effective as brand-name Lipitor at preventing a second heart attack?
Lee T
Harv Heart Lett; 2012 Jan; 22(5):8. PubMed ID: 22389921
[No Abstract] [Full Text] [Related]
34. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
35. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
[TBL] [Abstract][Full Text] [Related]
36. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
38. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
Mark DB; Knight JD; Cowper PA; Davidson-Ray L; Anstrom KJ
Am Heart J; 2008 Oct; 156(4):698-705. PubMed ID: 18926150
[TBL] [Abstract][Full Text] [Related]
39. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
